## PATENT ASSIGNMENT

## Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE	:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:		ASSIGNMENT		
CONVEYING PART	Y DATA			
		Name	Execution Date	٦
PATHWAY THERA	PEUTICS LIMITED		11/03/2010	
RECEIVING PARTY	' DATA			
Name:	PATHWAY THER	APEUTICS INC.		7
Street Address:	409 Illinois Street			
City:	San Francisco			
State/Country:				
State/Country: Postal Code:	CALIFORNIA 94158			
Postal Code:	94158 ERS Total: 10	Number		]
Postal Code: PROPERTY NUMB Property	94158 ERS Total: 10	Number 64359		]
Postal Code: PROPERTY NUMB Property Application Numbe	94158 ERS Total: 10 Type r: 611			
Postal Code: PROPERTY NUMB Property	94158 ERS Total: 10 Type r: 611 r: 612	64359		
Postal Code: PROPERTY NUMB Property Application Numbe Application Numbe	94158 ERS Total: 10 Type 611 r: 612 r: 612	64359 23687		
Postal Code: PROPERTY NUMB Property Application Numbe Application Numbe	94158 ERS Total: 10 Type 611 r: 612 r: 612 r: 127	64359 23687 47454		
Postal Code: PROPERTY NUMB Property Application Numbe Application Numbe Application Numbe	94158 ERS Total: 10 Type 611 r: 612 r: 612 r: 127 r: 611	64359 23687 47454 48251		
Postal Code: PROPERTY NUMB Property Application Numbe Application Numbe Application Numbe Application Numbe	94158 ERS Total: 10 Type 611 r: 612 r: 612 r: 611 r: 611 r: 611	64359 23687 47454 48251 64358		
Postal Code: PROPERTY NUMB Property Application Numbe Application Numbe Application Numbe Application Numbe Application Numbe	94158         ERS Total: 10         Type         r:       611         r:       612	64359 23687 47454 48251 64358 23684		
Postal Code: PROPERTY NUMB Property Application Numbe Application Numbe Application Numbe Application Numbe Application Numbe Application Numbe	94158         ERS Total: 10         Type         r:       611         r:       612         r:       613         r:       614         r:       615         r:       616         r:       613	64359 23687 47454 48251 64358 23684 47448		

## CORRESPONDENCE DATA

Fax Number:(858)314-1150Correspondence will be sent via US Mail when the fax attempt is unsuccessful.Phone:858-314-1200Email:scgenua@jonesday.com

PATENT REEL: 025375 FRAME: 0721

501351781

Correspondent Name: Address Line 1: Address Line 2: Address Line 4:	JONES DAY 222 East 41st Sandra Genua New York, NE\				
ATTORNEY DOCKET NU	MBER:	322610-600001			
NAME OF SUBMITTER:		Sandra Genua			
	Total Attachments: 2 source=Assignment_Pathway_Therapeutics_Limited_to_Pathway_Therapeutics_Inc#page1.tif source=Assignment_Pathway_Therapeutics_Limited_to_Pathway_Therapeutics_Inc#page2.tif				

#### ASSIGNMENT

WHEREAS, **PATHWAY THERAPEUTICS LIMITED**, a New Zealand Company, located at Level 10, 70 Symonds Street, Auckland, New Zealand, ASSIGNOR, is an owner of right, title, and interest in the inventions contained in the patent applications listed in **Table 1**, attached;

and WHEREAS, **PATHWAY THERAPEUTICS INC.**, a Delaware company, having a place of business at 409 Illinois Street, San Francisco, CA 94158, ASSIGNEE, is desirous of obtaining ASSIGNOR'S entire right, title and interest in, to and under the said inventions and the said applications:

NOW, THEREFORE, in consideration of good and valuable consideration, the receipt of which is hereby acknowledged, the said ASSIGNOR, has sold, assigned, transferred and set over, and by these presents does hereby sell, assign, transfer and set over, unto the said ASSIGNEE, its successors, legal representatives and assigns, its entire right, title and interest in, to and under the said inventions, and the said United States provisional applications and all applications claiming priority thereto under 35 U.S.C. §119(e) and divisions, renewals and continuations thereof, and all Patents of the United States which may be granted thereon and all reissues and extensions thereof; and all applications for industrial property protection, including, without limitation, all applications for patents, utility models, and designs which may hereafter be filed for said inventions in any country or countries foreign to the United States applications under the Patent Laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable; and all forms of industrial property protection, including, without limitation, patents, utility models, inventors' certificates and easigns which may be agained for said inventions in any country or countries foreign to the United States applications under the Patent Laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable; and designs which may be granted for said inventions in any country or countries foreign to the United States and all extensions, renewals and reissues thereof.

AND ASSIGNOR HEREBY authorizes and requests the Commissioner for Patents and any Official of any country or countries foreign to the United States, whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to the said ASSIGNEE, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

AND ASSIGNOR HEREBY covenants and agrees that ASSIGNOR has full right to convey the entire interest herein assigned, and that ASSIGNOR has not executed, and will not execute, any agreement in conflict herewith.

AND ASSIGNOR HEREBY further covenants and agrees that ASSIGNOR will communicate to the said ASSIGNEE, its successors, legal representatives and assigns, any facts known to ASSIGNOR respecting said inventions, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing, reissue and foreign applications, make all rightful oaths, and generally do everything possible to aid the said ASSIGNEE, its successors, legal representatives and assigns, to obtain and enforce proper protection for said inventions in all countries.

IN TESTIMONY WHEREOF, the undersigned Officer has affixed his or her signature.

Name: Julie Cherrington Title: CEO of Pathway Therapeutics Ltd.

Signature Date

STATE OF CALIFORNIA

COUNTY OF <u>Sum Francis</u>io

On 3 Nor, 2010 before me, <u>Michael Stephen Morres</u>, Notary Public, personally appeared <u>Julie</u> <u>Cherrington</u>, who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

)

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand Signature\_\_\_\_\_ (Seal)



$(\mathbf{r})$
<b>m</b>
$\checkmark$
<b>[</b> ]

232.610-688003         U.S.         61/164.359         05.27/09         Pyrimidinyl and 1.3.5-Triazinyl Benzimidazole Sufforamides and 232300-888008           1232010-888003         U.S.         61/237,645         09.3009         Pyrimidinyl and 1.3.5-Triazinyl Benzimidazole Sufforamides and 233210-08.8803           1232010-888008         U.S.         61/237,644         09.3009         Pyrimidinyl and 1.3.5-Triazinyl Benzimidazole Sufforamides and 235210-08.6803           120510-05008         AR         10.01 00996         03.26/10         Pyrimidinyl and 1.3.5-Triazinyl Benzimidazole Sufforamides and 235210-05008           120510-08008         PCT         D0.100906         03.26/10         Pyrimidinyl and 1.3.5-Triazinyl Benzimidazole Sufforamides and 235010-05008           120510-08008         PCT         PCTN/Z2010/000060         03.26/10         Pyrimidinyl and 1.3.5-Triazinyl Benzimidazole Sufforamides and 235010-05008           120510-08008         U.S.         61/164.358         03.27/09         Pyrimidinyl and 1.3.5-Triazinyl Benzimidazoles and Their Use in 235010-28008           125510-0890809         U.S.         61/164.358         03.27/09         Pyrimidinyl and 1.3.5-Triazinyl Benzimidazoles and Their Use in 235010-28008           125510-0890809         U.S.         61/164.358         03.27/09         Pyrimidinyl and 1.3.5-Triazinyl Benzimidazoles and Their Use in 235010-28008           1255310-0890809         U.S.	Docket No.	Country	Serial No.	Filed	Title
U.S.         61/223,687         07/07/09           8)         U.S.         61/247,454         09/30/09           8)         U.S.         61/247,454         09/30/09           8)         U.S.         61/247,454         09/30/09           8)         TW         099109225         03/26/10           9)         PCT         PCTN/Z2010/00060         03/26/10           10         U.S.         12/748,251         03/26/10           10         U.S.         12/748,251         03/26/10           10         U.S.         61/164,358         03/26/10           11         PCT         PCT/NZ2010/00061         03/26/10           12         PCT         PCT/NZ2010/00061         03/26/10           10         U.S.         61/247,448         09/30/09           11         U.S.         61/223,684         07/07/09           11         U.S.         61/221,448         03/26/10           11         U.S.         61/221,448         03/26/10           11         U.S.         61/2213         03/26/10           11         U.S.         61/2213         03/26/10           11         U.S.         61/2318,195         03/26/10 <td>322610-888003 (12633-003-888)</td> <td>U.S.</td> <td>61/164,359</td> <td>03/27/09</td> <td>Pyrimidinyl and 1,3,5-Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy</td>	322610-888003 (12633-003-888)	U.S.	61/164,359	03/27/09	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy
%         U.S.         61/247,454         09/30/09           %         AR         10 01 00996         03/26/10           %         TW         099109225         03/26/10           %         PCT         PCTNZ2010/00060         03/26/10           %         U.S.         12/748,251         03/26/10           %         U.S.         12/748,251         03/26/10           %         U.S.         61/164,358         03/26/10           %         U.S.         61/164,358         03/26/10           %         U.S.         61/247,482         03/26/10           %         U.S.         61/223,684         07/07/09           %         U.S.         61/247,448         07/07/09           %         U.S.         61/247,448         07/06/10           %         U.S.         61/247,448         07/06/10           %         U.S.         61/247,448         07/06/10           %         U.S.         61/218,195         03/26/10           %         U.S.         61/247,448         07/06/10           %         U.S.         61/247,448         07/06/10           %         U.S.         61/2318,195         03/20/10	322610-888006 (12633-006-888)	U.S.	61/223,687	07/07/09	Pyrimidinyl and 1,3.5-Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy
AR         10 01 00996         03/26/10           8)         TW         099109225         03/26/10           8)         TW         099109225         03/26/10           8)         PCT         PCT/NZ2010/000600         03/26/10           9)         U.S.         12/748,251         03/26/10           9)         U.S.         61/164,358         03/26/10           9)         U.S.         61/164,358         03/26/10           9)         U.S.         61/245,21         03/26/10           9)         D.S.         61/245,358         03/26/10           9)         U.S.         61/247,448         07/07/09           9)         U.S.         61/247,448         07/06/10         1           9)         U.S.         61/318,195         03/26/10         1           10)         U.S.         61/318,195         03/26/10         1           10)         U.S.         61/318,195         03/26/10         1           11)         U.S.         61/318,195         03/26/10         1           11)         U.S.         61/318,195         03/26/10         1           11)         U.S.         10.S.         03/26/10	322610-888008 (12633-008-888)	U.S.	61/247,454	09/30/09	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy
x         TW         099109225         03/26/10           x         PCT         PCT/NZ2010/00060         03/26/10           x         U.S.         12/748,251         03/26/10           x         U.S.         12/748,251         03/26/10           x         U.S.         61/164,358         03/26/10           x         U.S.         61/164,358         03/26/10           x         bPCT         PCT/NZ2010/00061         03/26/10           x         0.V.S.         61/223,684         07/07/09           x         U.S.         61/223,684         07/07/09           x         U.S.         61/218,195         03/26/10           x         U.S.         61/218,195         03/26/10           x         U.S.         61/218,195         03/26/10           x         U.S.         61/218,195         03/26/10           x         U.S.         61/233,684         07/06/10           x         U.S.         61/218,195         03/26/10           x         U.S.         61/231,128         07/06/10           x         U.S.         10.0102428         07/06/10           x         U.S.         12/831,128         07/06/	322610-036008 (12633-008-036)	AR	10 01 00996	03/26/10	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy
I         PCT         PCT/NZ2010/00060         03/26/10           0)         U.S.         12/748,251         03/26/10           0)         U.S.         61/164,358         03/26/10           0)         U.S.         61/164,358         03/26/10           0)         D.S.         61/164,358         03/26/10           0)         D.S.         61/223,684         07/07/09           0)         U.S.         61/247,448         09/30/09           0)         U.S.         61/247,448         09/30/09           0)         U.S.         61/247,448         07/06/10           0)         U.S.         61/218,195         03/26/10           1)         U.S.         61/218,195         03/26/10           1)         U.S.         61/2318,195         03/26/10           1)         U.S.         61/2318,195         03/26/10           1)         U.S.         61/247,448         09/30/09           1)         U.S.         61/247,448         03/26/10           1)         U.S.         61/2428         07/06/10           1)         U.S.         100102428         07/06/10           1)         U.S.         12/2313 <td< td=""><td>322610-185008 (12633-008-185)</td><td>TW</td><td>099109225</td><td>03/26/10</td><td>Pyrimidinyl and 1,3.5-Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy</td></td<>	322610-185008 (12633-008-185)	TW	099109225	03/26/10	Pyrimidinyl and 1,3.5-Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	322610-228008 (12633-008-228)	PCT	PCT/NZ2010/000060	03/26/10	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy
U.S. $61/164,358$ $03/27/09$ $BCT$ $PCT/NZ2010/00061$ $03/26/10$ $D.S.$ $61/223,684$ $07/07/09$ $U.S.$ $61/223,684$ $07/07/09$ $U.S.$ $61/247,448$ $09/30/09$ $U.S.$ $61/247,448$ $09/30/09$ $U.S.$ $61/247,448$ $09/30/09$ $D.S.$ $61/318,195$ $03/26/10$ $1$ $D.S.$ $PCT$ $PCT/05/10$ $1$ $D.S.$ $D.S.$ $07/06/10$ $1$ $D.S.$ $61/387,836$ $07/06/10$ $1$	322610-999008 (12633-008-999)	U.S.	12/748,251	03/26/10	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy
PCT         PCT/NZ2010/00061         03/26/10           0         U.S.         61/223,684         07/07/09           0         U.S.         61/247,448         09/30/09           0         U.S.         61/218,195         03/26/10           0         U.S.         61/318,195         03/26/10           1         U.S.         61/318,195         03/26/10           1         U.S.         61/318,195         03/26/10           1         TW         099122213         07/06/10           1         TW         099122213         07/06/10           1         PCT         PCT/NZ2010/000139         07/06/10           1         U.S.         12/831,128         07/06/10           1         U.S.         61/387,836         09/29/10	322610-888004 (12633-004-888)	U.S.	61/164,358	03/27/09	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles and Their Use in Cancer Therapy
U.S.         61/223,684         07/07/09           U.S.         61/247,448         09/30/09           U.S.         61/247,448         09/30/09           U.S.         61/318,195         03/26/10           U.S.         61/318,195         03/26/10           D.TW         09912213         07/06/10           D.TW         099122213         07/06/10           D.TW         099122213         07/06/10           D.TW         099122213         07/06/10           D.U.S.         PCT         PCT/NZ2010/000139         07/06/10           D.U.S.         12/831,128         07/06/10         1           D.U.S.         61/387,836         09/29/10         1	322610-228004 (12633-004-228)	PCT	PCT/NZ2010/000061	03/26/10	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles and Their Use in Cancer Therapy
U.S.         61/247,448         09/30/09           U.S.         61/318,195         03/26/10           U.S.         61/318,195         03/26/10           Dar         P100102428         07/06/10           TW         09912213         07/06/10           PCT         PCT/NZ2010/000139         07/06/10           U.S.         12/831,128         07/06/10           U.S.         61/387,836         07/06/10	322610-888005 (12633-005-888)	U.S.	61/223,684	07/07/09	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles and Their Use in Cancer Therapy
U.S.         61/318,195         03/26/10           AR         P100102428         07/06/10           TW         099122213         07/06/10           PCT         PCTNZ2010/000139         07/06/10           U.S.         12/831,128         07/06/10           U.S.         61/387,836         07/06/10	322610-888007 (12633-007-888)	U.S.	61/247,448	09/30/09	Pyrimidinyl and 1.3,5-Triazinyl Benzimidazoles and Their Use in Cancer Therapy
AR         P100102428         07/06/10           )         TW         099122213         07/06/10           )         PCT         PCT/NZ2010/000139         07/06/10           )         U.S.         12/831,128         07/06/10           )         U.S.         61/387,836         09/29/10	322610-888009 (12633-009-888)	U.S.	61/318,195	03/26/10	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles and Their Use in Cancer Therapy
) TW 099122213 07/06/10 ) PCT PCT/NZ2010/000139 07/06/10 ) U.S. 12/831,128 07/06/10 ) U.S. 61/387,836 09/29/10	322610-036009 (12633-009-036)	AR	P100102428	07/06/10	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles and Their Use in Cancer Therapy
PCT         PCT/NZ2010/000139         07/06/10           U.S.         12/831,128         07/06/10           U.S.         61/387,836         09/29/10	322610-185009 (12633-009-185)	TW	099122213	07/06/10	Pyrimidinyl and 1.3,5-Triazinyl Benzimidazoles and Their Use in Cancer Therapy
) U.S. 12/831,128 07/06/10 ) U.S. 61/387,836 09/29/10	322610-228009 (12633-009-228)	PCT	PCT/NZ2010/000139	07/06/10	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles and Their Use in Cancer Therapy
) U.S. 61/387,836 09/29/10	322610-999009 (12633-009-999)	U.S.	12/831,128	07/06/10	Pyrimidinyl and 1,3,5-Triazinyl Benzimidazoles and Their Use in Cancer Therapy
	322610-888010 (12633-010-888)	U.S.	61/387,836	09/29/10	1,3,5-Triazinyl Benzimidazole Sulfonamides and Their Use in Cancer Therapy

# RECORDED: 11/16/2010

## PATENT REEL: 025375 FRAME: 0724

<del>,.....</del>